scholarly journals Mckittrick-wheelock syndrome: a rare cause of serious secretory diarrhoea.

2021 ◽  
Vol 44 (5) ◽  
pp. 187-189
Author(s):  
E Merino Gallego ◽  
E Martínez Amate
Keyword(s):  
Secretory Diarrhoea

Resumen El síndrome de McKittrick-Wheelock (SMW) es una entidad rara caracterizada por un cuadro de diarrea secretora que puede llegar a ser grave y conducir a trastornos hidroelectrolíticos y disfunción renal, secundario a la presencia de un adenoma velloso colorrectal hipersecretor. El tratamiento definitivo es la resección quirúrgica del adenoma responsable, pudiendo administrarse inhibidores de la prostaglandina E2 como terapia puente.

scholarly journals Effect of two new antisecretory drugs on fluid and electrolyte transport in a patient with secretory diarrhoea.

Gut ◽  
1986 ◽  
Vol 27 (5) ◽  
pp. 581-586 ◽  
Author(s):  
C Edwards ◽  
P A Cann ◽  
N W Read ◽  
C D Holdsworth
Keyword(s):  
Electrolyte Transport ◽  
Antisecretory Drugs ◽  
Secretory Diarrhoea

The effects of loperamide, or loperamide plus simethicone, on the distribution of gut water as assessed by MRI in a mannitol model of secretory diarrhoea

2012 ◽  
Vol 36 (1) ◽  
pp. 64-73 ◽  
Author(s):  
E. Placidi ◽  
L. Marciani ◽  
C. L. Hoad ◽  
A. Napolitano ◽  
K. C. Garsed ◽  
...  
Keyword(s):  
Secretory Diarrhoea

Small intestinal segment perfusion test in piglets: future applications in studying probiotics-gut crosstalk in infectious diarrhoea?

2010 ◽  
Vol 1 (4) ◽  
pp. 439-445 ◽  
Author(s):  
J. van der Meulen ◽  
M. Hulst ◽  
M. Smits ◽  
T. Schuurman
Keyword(s):  
Physiological Response ◽  
Enterotoxigenic Escherichia Coli ◽  
Weaned Piglets ◽  
Infectious Diarrhoea ◽  
Secretory Diarrhoea ◽  
Prevention And Treatment ◽  
Small Intestinal ◽  
Traveller’S Diarrhoea ◽  
Intestinal Compartments

Worldwide infectious diarrhoea, mainly caused by rotavirus and enterotoxigenic Escherichia coli (ETEC), accounts for a large part of deaths in children. ETEC is also the main cause of traveller's diarrhoea. Probiotics are promising for prevention and treatment of diarrhoea, but there is insufficient evidence to support the use of any specific probiotic or probiotics in general. Because of the sensitivity of suckling and weaned piglets for ETEC, piglets are a good model for infectious diarrhoea in infants and traveller's diarrhoea. Just as in human the efficacy of probiotics in diminishing diarrhoea and improving growth in suckling and weaned piglets is not uniform. A piglet model of infectious diarrhoea provides access to intestinal compartments that are not easily accessible in infants. In an in situ piglet model of secretory diarrhoea, the functional physiological response to ETEC and the concomitant host genome response to ETEC and probiotics may be tested. This will provide new insights in the complex crosstalk between ETEC, probiotics and the gut in the future.

The mechanism of secretory diarrhoea in trichuris dysentery syndrome

1995 ◽  
Vol 108 (4) ◽  
pp. A318
Author(s):  
EN Robinson ◽  
RE Young ◽  
ES Cooper
Keyword(s):  
Secretory Diarrhoea

scholarly journals Congenital secretory diarrhoea caused by activating germline mutations inGUCY2C

Gut ◽  
2015 ◽  
Vol 65 (8) ◽  
pp. 1306-1313 ◽  
Author(s):  
Thomas Müller ◽  
Insha Rasool ◽  
Peter Heinz-Erian ◽  
Eva Mildenberger ◽  
Christian Hülstrunk ◽  
...  
Keyword(s):  
Germline Mutations ◽  
Secretory Diarrhoea

Clinical and pathophysiological aspects of somatostatin and the gastrointestinal tract

1987 ◽  
Vol 116 (4_Suppla) ◽  
pp. S19-S25 ◽  
Author(s):  
C. B.H.W. Lamers
Keyword(s):  
Gastrointestinal Tract ◽  
Gastrointestinal Haemorrhage ◽  
Somatostatin Analogues ◽  
Exocrine Secretion ◽  
Somatostatin Analogue ◽  
Cell Hyperplasia ◽  
Secretory Diarrhoea ◽  
D Cell ◽  
Long Acting ◽  
Clinical Conditions

Abstract. Somatostatin is present in the gastrointestinal tract in appreciable amounts. The highest concentrations of the polypeptide are found in the stomach, the upper small intestine, and the pancreas. Within the gastrointestinal tract, somatostatin inhibits various functions, including endocrine and exocrine secretion, motility, blood flow, absorption, and growth. The polypeptide regulates these functions by endocrine, paracrine, neurocrine or luminal mechanisms. Abnormalities of endogenous somatostatin have been implicated in several gastrointestinal disorders, including the somatostatinoma syndrome, antroduodenal D-cell hyperplasia, peptic ulcer, obesity, and liver cirrhosis. Because of its potent inhibitory effects, somatostatin or somatostatin-analogues have been used as therapeutic agents in various clinical conditions, such as upper gastrointestinal haemorrhage, endocrine pancreatic tumours, gastrointestinal and pancreatic fistulas, pancreatitis, secretory diarrhoea, and dumping syndrome. The recent availability of the synthetic long-acting somatostatin-analogue SMS 201-995 (Sandostatin) has greatly facilitated the therapeutical application of somatostatin-polypeptides.

scholarly journals Case Series of Metastatic VIPoma With Partial Response to Somatostatin Receptor Ligand and Review of Therapeutic Options

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A993-A993
Author(s):  
Lim Sue Wen ◽  
Goh Kian Guan ◽  
Jin Hui Ho ◽  
Serena Sert Kim Khoo ◽  
Zanariah Hussein
Keyword(s):  
Targeted Therapy ◽  
Disease Control ◽  
Radionuclide Therapy ◽  
Symptom Relief ◽  
Somatostatin Receptor ◽  
Case Series ◽  
Peptide Receptor Radionuclide Therapy ◽  
Cytotoxic Chemotherapy ◽  
Peptide Receptor ◽  
Secretory Diarrhoea

Abstract Background: Vasoactive intestinal polypeptide secreting islet cell tumors (VIPoma) are rare neuroendocrine tumors of pancreatic origin, characterized by secretory diarrhoea and electrolyte imbalances. Metastasis, commonly hepatic, frequently occur at diagnosis in up to 80% patients. Surgery of the primary tumour remains the gold standard management and in metastatic tumors, somatostatin receptor ligands (SRL) are the drugs of choice for symptom relief and disease control. Some patients will require other approaches to control symptoms, such as liver-targeted therapy, peptide receptor radionuclide therapy (PRRT) or chemotherapy. We describe a case series of metastatic VIPoma which partially-responded to SRL and review of other treatment modalities to achieve disease and symptom control. Case: We report 3 cases, ages 37 to 58 years, with metastatic VIPoma whom presented with secretory diarrhoea, hypokalaemia, achlorhydria and elevated serum VIP levels. CT and 68Gallium PET-CT imaging identified metastases in liver, bone, lungs, spleen and lymph nodes. One case underwent distal pancreatectomy and splenectomy at diagnosis and two cases were advanced and non-resectable. All received long-acting SRL initially and achieved partial control of the gastrointestinal symptoms. Two cases underwent Peptide Receptor Radionuclide Therapy (PRRT) and one case received cytotoxic chemotherapy. Two patients have progressive disease and one succumbed to advanced disease. For inoperable disease, PRRT is useful adjuvant therapy for symptom relief and may improve progression free survival (PFS). Cytotoxic chemotherapy is an option for patients with progressive or symptomatic unresectable tumor. Chemoembolization or liver-targeted therapy are used in liver metastasis for loco-regional control. Alfa-interferon and targeted therapies such as everolimus and sunitinib are other treatment options that can be considered. Conclusion: Metastatic VIPoma remains a challenging disease to manage, requiring multimodal treatment approaches. With timely diagnosis and advancing therapeutic options, more patients can achieve improved symptom and disease control as well as increased survival.

scholarly journals Search for the ideal oral rehydration solution: studies in a model of secretory diarrhoea.

Gut ◽  
1991 ◽  
Vol 32 (11) ◽  
pp. 1314-1320 ◽  
Author(s):  
E J Elliott ◽  
A J Watson ◽  
J A Walker-Smith ◽  
M J Farthing
Keyword(s):  
Oral Rehydration Solution ◽  
Oral Rehydration ◽  
Solution Studies ◽  
Secretory Diarrhoea ◽  
Rehydration Solution ◽  
The Ideal

A pill for secretory diarrhoea on the horizon?

The Lancet ◽  
2002 ◽  
Vol 360 (9348) ◽  
pp. 1845
Author(s):  
David M Lawrence
Keyword(s):  
Secretory Diarrhoea
Sign in / Sign up

Export Citation Format

Share Document